As more doctors become familiar with (OTC:BSEM)’s unique technology, it could open doors to many revenue opportunities and stellar growth on Wall Street. Regenerative medicine is the future, and it comes as no surprise that the biotech space is all over it. Who will be the leading biotech companies utilizing regenerative medicine in the future? That’s the million-dollar question. One emerging company could have explosive growth potential ahead in this rising arena. The Company is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. These allografts are not just any allografts. They are best-in-class perinatal tissue allografts. The company is focused on the diabetic wound care market and the advanced wound care market: two multi-billion-dollar markets that could equate to explosive revenues all while helping patients. This company recently hit a huge milestone, receiving Investigational Review Board (IRB) approval for a clinical study that aims to investigate the utilization and effects of the company's Vendaje wound care products in Diabetic Foot Ulcers (DFU). DFUs are a significant risk for people with diabetes. Between 14 and 24 percent of people who develop DFU will require an amputation. As BioStem works to achieve its mission of delivering cutting-edge wound care management products, it is strategically addressing a significant market opportunity, adding long-term value for shareholders. See why this underfollowed biotech stock could be at a value right now! | 
没有评论:
发表评论